Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.64 |
| ▸ | MDM4 | O15151 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.53 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29352428 | 1.00 | CASP3 (0.64) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL29367388 | 1.00 | CASP3 (0.64) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL30055375 | 1.00 | CASP3 (0.64) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL378041 | 1.00 | CASP3 (0.64) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL1486199 | 1.00 | CASP3 (0.64) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL30988976 | 0.93 | CASP3 (0.56) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL29401049 | 0.92 | CASP3 (0.60) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL29047043 | 0.91 | CASP3 (0.59) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL30656568 | 0.91 | MDM4 (0.59) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL29053258 | 0.91 | CASP3 (0.58) | CASP3MDM4TP53KMT2AMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121575079-A | SGLT1/2 double-target inhibitor, screening method and application thereof, and diabetes treatment drug | 广东药科大学 | 2026-02-27 | — | — | CN | claimed |
| CN-102643330-B | A kind of synthetic method and its medical application of bone target medicine Aspartate hexapeptide Danshensu | 广东医科大学 | 2018-10-19 | — | — | CN | claimed |
| CN-102643330-A | Synthetic method for aspartate hexapeptide danshensu as bone targeted drug and medical application of aspartate hexapeptide danshensu | GUANGDONG MEDICAL COLLEGE | 2012-08-22 | — | — | CN | claimed |
| CN-121575079-A | SGLT1/2 double-target inhibitor, screening method and application thereof, and diabetes treatment drug | 广东药科大学 | 2026-02-27 | — | — | CN | disclosed |
| CN-118184532-A | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-06-14 | — | — | CN | disclosed |
| CN-118146313-A | Self-assembled short peptide and application thereof in hemostasis and injury repair | 成都赛恩贝外科学研究院 | 2024-06-07 | — | — | CN | disclosed |
| CN-113454058-B | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-03-22 | — | — | CN | disclosed |
| CN-117500819-A | Lipid and composition | 相互药工株式会社 | 2024-02-02 | — | — | CN | disclosed |
| CN-116120585-B | Preparation method for preparing amino acid photocatalytic decarboxylation oxidation product by means of photocatalyst | 北京化工大学 | 2023-11-14 | — | — | CN | disclosed |
| CN-117043679-A | Composition for forming resist underlayer film having protected alkaline organic group | 日产化学株式会社 | 2023-11-10 | — | — | CN | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20010038824-A1 | Intranasal cyclic peptide formulations | BASILEA PHARMACEUTICA AG (CH) | 2001-11-08 | — | — | US | disclosed |
| CN-1313846-A | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cystenine proteases | IDUN PHARMACEUTICALS INC (US) | 2001-09-19 | — | — | CN | disclosed |
| WO-2001052894-A2 | NASALLY ADMINISTRABLE CYCLIC PEPTIDE COMPOSITIONS | BASILEA PHARMACEUTICA AG (CH) | 2001-07-26 | — | — | WO | disclosed |
| EP-1100816-A1 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | F. HOFFMANN-LA ROCHE AG (CH) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000005251-A1 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | F. HOFFMANN-LA ROCHE AG (CH) | 2000-02-03 | — | — | WO | disclosed |
| CN-1189833-A | Amidine derivatives useful as anti-platelet aggreation inhibitors and vasodilators | SEARLE & CO (US) | 1998-08-05 | — | — | CN | disclosed |
| EP-0673388-A1 | DOUBLE CHAIN PEPTIDE COMPOUNDS HAVING HEMOREGULATORY ACTIVITY | NYCOMED IMAGING AS (NO) | 1995-09-27 | — | — | EP | disclosed |
| CN-1086221-A | Peptide compounds | HAFSLUND NYCOMED AS (NO) | 1994-05-04 | — | — | CN | disclosed |
| WO-1991005564-A1 | SYNTHESIS AND USE OF AMINO ACID FLUORIDES AS PEPTIDE COUPLING REAGENTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1991-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | CASP3 2783/4885MDM4 1648/4885TP53 614/4885 |
| US-20010038824-A1 | Intranasal cyclic peptide formulations | VIP, NPPA, SSTR5 | CASP3 2874/4885MDM4 3435/4885TP53 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.